Some women may shed more than men, but this depends on genetics, stress levels, hormonal changes, styling preferences, and health status. Research shows that men are more likely to experience genetic ...

FDA expands Sogroya approval for pediatric patients with Noonan syndrome, idiopathic short stature, and those born small for gestational age.

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments.

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other ...

What began as a single clinic in Colorado has evolved into a well-regarded provider of hormone optimization and replacement care, now serving more than 10,000 patients.

In today’s Pharmaceutical Executive Daily, the FDA approves an expanded indication for Palynziq in patients aged 12 and older ...

Novo Nordisk’s Sogroya is now approved for children aged 2.5 or older with idiopathic short stature, small for gestational age, and Noonan Syndrome.

Sermorelin.com Unveils Telehealth Peptide Treatment for Lean Mass Preservation Sheridan, United States - February 27, ...

Investing.com -- Novo Nordisk announced late Friday that the US Food and Drug Administration has approved three new indications for once-weekly Sogroya (somapacitan-beco) injection 5 mg, 10 mg, or 15 ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...

After 16 weeks of testing, we noticed visible results. Here are our favorite red light therapy devices for hair growth.

The FDA has approved three new pediatric indications for somapacitan-beco, a once-weekly, long-acting growth hormone injection, according to a press release issued by Novo Nordisk.Somapacitan-beco ...